NCT05365880

Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Utah · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Determine the effects of sphenopalatine ganglion (SPG) block in post-stroke headache.

Detailed description

The purpose of this study is to determine if sphenopalatine ganglion (SPG) block is a safe and effective treatment for acute post-stroke headache. Current literature lacks randomized controlled studies regarding the efficacy of different treatment modalities for acute post-stroke headache; additionally, there are no evidence-based guidelines for the treatment of acute post-stroke headache. Sphenopalatine ganglion block is a non-invasive procedure where an anesthetic agent is injected into the nares, reaching the SPG to relieve pain and autonomic features. This treatment has been effective in a variety of headache types but to our knowledge has not been studied in acute post-stroke headache.

Conditions

• Headache
• Stroke
• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Liquid Lidocaine	The investigational treatment is 2 mL of aqueous 2% lidocaine.
DRUG	Placebo	The active placebo comparator will be provided to participant.

Timeline

• Start date: 2022-03-23
• Primary completion: 2025-03-22
• Completion: 2025-06-01
• First posted: 2022-05-09
• Last updated: 2024-11-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study